BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands) are some of the major players in the human organoids market among others.
Different Growth Strategies Adopted by Them:
The analysis of market developments between 2017 and 2020 revealed that several growth strategies such as research collaborations were adopted by market players to strengthen their product portfolios and maintain a competitive position in the human orgnaoids market.
Expected Revenue Growth:
The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5 %.
Major Growth Boosting Factors:
Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids market.
BioIVT was founded in 1981 and is headquartered in New York, US. The company is a leading global provider of biological specimens, including human tissues, cell products, blood, and other biofluids. The company provides a wide range of services, ranging from target and biomarker validation, phenotypic assays to characterize novel therapeutics, and clinical assay development to in vitro hepatic modeling solutions. It is a supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes.
Some of the major end users of the company’s products are research organizations, pharmaceutical and biotechnological companies, medical device companies, and academic research institutes. BioIVT offers its products and services across North America, the Asia Pacific, Europe, and the Middle East & Africa. The company has two distributors in the Asia Pacific region, namely, Veritas Corporation (Japan) and Research Institute for Liver Diseases (Shanghai) Co., Ltd. (China).
Thermo Fisher Scientific is engaged in the development, manufacturing, and marketing of analytical instruments, reagents and consumables, equipment, and software products. The company operates its businesses through four segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services. The human liver model business comes under the Life Sciences Solutions segment. The company pursues both organic and inorganic growth strategies.
The company has a strong geographic presence in more than 50 countries across North America, Asia Pacific, Europe, and Latin America. Its major subsidiaries are Thermo Scientific Microbiology Sdn. Bhd (Malaysia), Thermo Scientific Microbiology Pte Ltd. (Singapore), Laboratory Management Systems, Inc. (US), Thermo Dutch Holdings Limited Partnership (UK), Thermo EGS Gauging LLC (US), Fisher Clinical Services Limited Liability Company (Russia), Fisher Clinical Services Japan K.K., and Thermo Fisher Scientific C.V. (Netherlands).
Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally
Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
